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58 Poster Session Ithat the latest observed relapse after long term followup occurred at
27 months post-HCT. Thus, our data demonstrates that the condi-
tioning regimen of FTBI/VP16 1/- cyclophosphamide confers
long term cure rates in Ph1 ALL patients and that disease status
at the time of HCT is one of the most important predictors of
outcome.
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Cell dosage is a limiting factor for cord blood transplantation
(CBT) of adult patients. Most CB banks practice red cell deple-
tion/reduction techniques to save storage space, which incur signif-
icant nucleated cell loss after processing. Plasma depletion (PD),
eliminating the post-thaw washing step (NW), and the use of
double cord transplants (2X) are strategies used to maximize cell1-Yr
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45 ± 9%recovery, reduce CB volume, and increase cell dose. An audited ret-
rospective analysis was performed on all adult patients with malig-
nancies that have available survival data. There were 107 patients
transplanted with 130 PD CB. 56 patients (52%) had double cords
(2X) with at least one PD CB. Indications for transplant included:
AML (n 5 34), ALL (n 5 31), CML (n 5 13), lymphoma (n 5
10) and other malignancies (n 5 19). Of the patients with known
IBMTR disease status, 28% had early disease, 32% intermediate,
and 40% advanced. The median age was 35 years old (range 9.6–
63); median weight 68 kg (range 50–141); male sex 52%. Transplant
characteristics indicated a median # HLA ABDR matches of 4.0;
median pre-freeze PD CB TNC dose 3.4  107/kg; median post-
thaw PD CB TNC dose as reported by transplant centers 2.5 
107/kg; median pre-freeze PD CB CD341 dose 1.1  105/kg;
22% transplants outside of U.S.; 53% of the transplanted CB units
were washed post-thaw (W) and 38% were NW, with 8% unavail-
able post-thaw data. Results for all adult patients with malignancies,
single-cord (1X) patients, 2X patients, washed CB patients, and
NW CB patients are summarized below. Foregoing post-thaw
wash significantly decreased the incidence of extensive chronic
GvHD (cGvHD) (P 5 0.05) while increasing the incidence of lim-
ited cGvHD (P5 0.02), without increasing the relapse rate. 2X pa-
tients did not have higher acute GvHD (aGvHD) rate or lower
relapse than 1X patients. These results demonstrate that 1X or 2X
CBT using PD CB may be performed safely and effectively in adult
patients, and avoidance of post-thaw wash for PD CB may reduce
the rate of extensive cGvHD and achieve excellent overall and re-
lapse-free survival (OS & RFS).154
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Since granulocyte colony-stimulating factor (G-CSF) has been
shown to increase the susceptibility of some myeloid leukemia cells
to cytarabine in vitro, it has been used clinically in combination with
cytarabine for refractory acute myelogenous leukemia (AML) or
myelodysplastic syndrome. We retrospectively evaluated the effi-
cacy and safety of total body irradiation (TBI) and G-CSF-com-
bined high-dose cytarabine as a conditioning regimen for
allogeneic hematopoietic stem cell transplantation (HSCT) in pa-
tients with de novo AML. The conditioning regimen consisted of
12 Gy of TBI and high-dose cytarabine (3 g/m2) every 12 hours
for 4 days combined with continuous administration of G-CSF.
The stem cell sources were bone marrow or peripheral blood
stem cells from human leukocyte antigen (HLA)-identical siblings
(n 5 24) and bone marrow from HLA serologically matched unre-
lated donors (n5 26). Fifty patients (median age, 38 year-old) were
evaluated. At HSCT, AML was in the first or second complete re-
mission (CR) in 35 patients, and in the advanced stages in 15 pa-
tients. Thirty-six of 50 patients are currently alive with a median
follow-up period 5.6 years (range, 1.1–12.1 years). The 5-year esti-
mated overall survival and disease-free survival rates were 85.5% (95
CI, 73.7%-97.3%) and 82.1% (95 CI, 69.0%-95.2%) in patients
with AML in the first or second CR, 46.7% (95% CI, 21.4%-
72.0%) and 40.0% (95% CI, 15.3%-64.7%) in patients with AML
in the advanced stages. The 2-year cumulative incidence of
transplant-related mortality of all patients was 10.4% (95% CI,
1.8%-18.6%). Factors affecting the survival were disease status at
transplant and risk categories of cytogenetic analysis by multivariate
analysis. These results suggest that G-CSF-combined high-dose cy-
tarabine could be a promising component of the conditioning reg-
imen of allogeneic HSCT for AML, providing a high survival and
a low transplant-related mortality.
